Physicians' Academy for Cardiovascular Education

HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

Dec. 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Nanotherapeutic solutions to reduce atherosclerotic processes in the blood vessel

Mar. 16, 2017 - VBWG - ACC 2017 - John Cooke, MD, PhD - Houston, TX, USA

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

HIV as a model to study effect of chronic inflammation on CV risk

Mar. 16, 2017 - VBWG ACC 2017

Lowering inflammation to address residual CV risk

Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

May 31, 2017 - ESC HF 2017, Paris

Emerging therapeutic areas in lipid management and CV disease

Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA

Disappointing results with therapy for acute heart failure

Apr. 30, 2017 - ESC HF 2017, Paris

Initiating digoxin in AF patients associated with early hazard of sudden death

Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

In real-world setting three SGLT2 inhibitors associated with decreased CVD risk

A multinational observational analysis

Aug. 16, 2017 - Birkeland KI, et al. - Lancet Diabetes Endocrinol 2017

Also in a real-world setting, new use of SGLT2 inhibitors dapagliflozin, empagliflozin and canagliflozin was associated with a decreased cardiovascular (CV) disease and mortality risk.

PCSK9 antibody does not increase HbA1c, fasting glucose or diabetes risk

Aug. 16, 2017 - Sattar N, et al. - Am J Cardiol 2017

In the OSLER-1 and OSLER-2 open-label extension studies, treatment with evolocumab for the duration of 1 year had no apparent effect on glucose homeostasis, but led to a slight weight increase.

Improvement quality of life with sacubitril/valsartan in heart failure

Aug. 15, 2017 - Lewis EF, et al. - Circulation: Heart failure 2017

Health-related quality of life specific to heart failure was significantly improved with sacubitril/valsartan compared with enalapril in the PARADIGM-HF trial.

Bempedoic acid/ezetimibe combination plus atorvastatin robustly reduced LDL in phase 2

Aug. 15, 2017 - news

Targeting complementary mechanisms of action with bempedoic acid and ezetimibe on top of a statin in hypercholesterolemia, robustly reduced LDL-c levels as well as hsCRP, was safe and well tolerated in a 6-week phase 2 trial.

ApoA-I not superior to HDL-c to predict coronary heart disease

Aug. 10, 2017 - Van Capelleveen JC, et al. - JAHA 2017

In the EPIC-Norfolk study and two validation cohorts, 4x4 interquartile comparisons did not show an association of ApoA-I levels with CHD risk within HDL-c quartiles. In contrast, risk was even increased with ApoA-I levels in some quartiles, as were prevalence of CHD risk factors.

Effect SGLT2 inhibitors on heart failure by sodium-hydrogen exchange?

Proposal of a Novel Mechanism of Action

Aug. 10, 2017 - Packer M, et al. - JAMA cardiol 2017

In this special communication, it is speculated that SGLT2 inhibitors affect the action of sodium-hydrogen exchangers (NHEs) and thereby sodium levels in kidneys and cardiomyocytes of the heart.

Air pollution and traffic noise associated with increase in CVD risk factors

Aug. 9, 2017 - Cai Y, et al. - Eur Heart J 2017

In two large European cohorts, long-term exposure to road traffic noise and ambient air pollution were significantly associated with increased hsCRP, blood glucose and lipids.

PCSK9 loss-of-function variants associate with lower LDL-C

Aug. 9, 2017 - Kent ST, et al. - Circ Cardiovasc Genet. 2017

A large meta-analysis of nine studies confirmed association of PCSK9 loss-of-function variants with lower LDL-C levels and lower coronary heart disease risk, but not with stroke risk.

Benefits diabetic patients with dual GIP/GLP-1 receptor agonist

Aug. 9, 2017 - Frias JP, et al. - Cell Metab. 2017

The dual GIP/GLP-1 receptor agonist NNC0090-2746 significantly improved glycemic control and reduced body weight, total cholesterol and leptin levels in diabetic patients on metformin.

PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies

Aug. 25, 2017 - Barcelona, Spain

EBAC-accredited symposium to be held during ESC 2017 in Barcelona, Spain

Managing Diabetes & CVD: Is epigenetics a new way forward?

Aug. 25, 2017 - Barcelona, Spain

EBAC-accredited symposium to be held during ESC 2017 in Barcelona, Spain

Modern management of diabetes in cardiology: Impact of SGLT2 inhibition on cardiovascular outcomes and heart failure

Aug. 27, 2017 - ESC, Barcelona, Spain

CME accredited sympsoium to be held during ESC 2017 in Barcelona Spain